In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn's disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX®, which was recently approved for mild-to-moderate ulcerative colitis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nielsen, O. H. & Ainsworth, M. A. Tumor necrosis factor inhibitors for inflammatory bowel disease. N. Engl. J. Med. 369, 754–762 (2013).
D'Haens, G. R. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106, 199–212 (2011).
Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2013.05.048.
Sandborn, W. J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2013.06.010.
Danese, S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61, 918–932 (2012).
Cominelli, F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N. Engl. J. Med. 369, 775–776 (2013).
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369, 711–721 (2013).
Travis, S. P. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut http://dx.doi.org/10.1136/gutjnl-2012-304258.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. Danese has served as a speaker, a consultant and an advisory board member for Abbott Laboratories, Abbvie, Actelion, Alphawasserman, Astra Zeneca, Cellerix, Celltrion, Cosmo Pharmaceuticals, Merck & Co, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, Schering-Plough, Tigenix, UCB Pharma and Vifor. L. Peyrin-Biroulet has received consulting fees from Abbott, BMS, Boehringer-Ingelheim, Celltrion, Ferring, Genentech, Hospira, Janssen, Merck, Mitsubishi, Norgine, Pharmacosmos, Pilège, Shire, Takeda, Therakos, Tillots, UCB-pharma and Vifor. He has also received lecture fees from Abbott, Ferring, HAC-pharma, Janssen, Merck, Norgine, Therakos, Tillots and Vifor.
Rights and permissions
About this article
Cite this article
Danese, S., Peyrin-Biroulet, L. Enriching the therapeutic armamentarium for IBD. Nat Rev Gastroenterol Hepatol 11, 84–86 (2014). https://doi.org/10.1038/nrgastro.2013.246
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.246
